Clinical Trials Directory

Trials / Completed

CompletedNCT03177668

Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma

Phase I/II Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Kissei Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to examine tolerability, safety, and pharmacokinetics of YS110 intravenous administration in patients with malignant pleural mesothelioma and to preliminarily examine the anti-tumor effect of YS110.

Conditions

Interventions

TypeNameDescription
DRUGYS110Intravenous administration

Timeline

Start date
2017-08-08
Primary completion
2020-02-05
Completion
2020-02-05
First posted
2017-06-06
Last updated
2020-09-25

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT03177668. Inclusion in this directory is not an endorsement.